FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2010-2011 May 6, 2004 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Neuroblastoma is the most common form of malignant solid tumor during childhood. Japan is the only country in which mass screening for neuroblastoma has been adopted as a national policy, and the program has been conducted since 1984. In 2001, urine samples from 1,170,662 infants six months of age (90.4 percent of eligible infants of that age in Japan) were tested for homovanillic acid and vanilmandelic acid (metabolites of catecholamines produced by neuroblastoma) by high-performance liquid chromatography, and 180 cases of neuroblastoma were detected.

The April 4, 2002, issue of the Journal included reports of screening studies . . . [Full Text of this Article]

This article has been cited by other articles:

• Soderstrom, L., Woods, W. G., Bernstein, M., Robison, L. L., Tuchman, M., Lemieux, B. (2005). Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening. JNCI J Natl Cancer Inst 97: 1118-1124 [Abstract] [Full Text]